MetaCap

NewAmsterdam Pharma N.V. (NAMS) vs Perrigo (PRGO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Perrigo (PRGO) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 26.1% versus a loss of 51.9%. Over five years, NAMS leads with a +88.0% price change compared with -57.8% for PRGO. Perrigo is the larger company by market cap ($2.21 billion vs $2.21 billion), about 1.0 times the size.

Perrigo pays a dividend yielding 7.28%, while NewAmsterdam Pharma N.V. does not currently pay one. Perrigo converts more of its revenue into profit, with a net margin of -33.5% versus -905.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NAMS-51.89%PRGO+26.11%
+38%-9%-56%
Nov 21, 20251 yearNov 20, 2026
NAMS+87.47%PRGO-61.25%
+340%+122%-97%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NAMS versus PRGO key metrics
MetricNAMSPRGO
Share price$18.41$15.94
Market cap$2.21B$2.21B
1-day change-5.64%-0.62%
YTD return-47.52%+14.51%
1-year return-51.89%+26.11%
5-year return+88.05%-57.81%
Forward P/E—6.94
EPS (TTM)$-1.69$-12.47
Dividend yield0.00%7.28%
Annual dividend$0.00$1.16
Revenue (latest FY)$22.50M$4.25B
Revenue growth (YoY)-50.61%-2.75%
Net income (latest FY)$-203.82M$-1.43B
Gross margin—35.14%
Operating margin-1002.90%-26.39%
Net margin-905.74%-33.51%
52-week high$42.21$17.07
52-week low$17.90$9.23
Distance from 52-week high-56.38%-6.62%
Analyst consensusstrong_buybuy
Avg. price target upside+174.85%+12.92%
Average volume1.66M2.54M
Shares outstanding119.93M138.80M
Employees1008,100
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PRGO has outperformed NAMS by 78.0 percentage points over the past year.
  • Perrigo offers a meaningfully higher dividend yield (7.28% vs 0.00%).
  • Perrigo is more profitable, keeping -33.5 cents of every revenue dollar as net income versus -905.7 cents for NewAmsterdam Pharma N.V..
  • Perrigo grew revenue faster in its latest fiscal year (-2.75% vs -50.61%).

About NewAmsterdam Pharma N.V.

NAMS stock →

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

About Perrigo

PRGO stock →

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees

NAMS vs PRGO FAQ

Which is bigger, NewAmsterdam Pharma N.V. or Perrigo?

Perrigo (PRGO) is larger, with a market capitalization of $2.21B compared with $2.21B for NewAmsterdam Pharma N.V. (NAMS).

Which stock has performed better over the past year, NAMS or PRGO?

PRGO returned +26.11% over the past 12 months, compared with -51.89% for NAMS (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, NewAmsterdam Pharma N.V. or Perrigo?

Perrigo pays a dividend yielding 7.28%, while NewAmsterdam Pharma N.V. does not currently pay a regular dividend.

Are NewAmsterdam Pharma N.V. and Perrigo in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons